Examining the role of neoadjuvant androgen deprivation in patients undergoing prostate brachytherapy

Journal of Clinical Oncology

Volumn 18, Issue 6, 2000, Pages 1187-1192

  Potters, Louis ^a   Torre, Taryn ^a   Ashley, Richard ^a   Leibel, Steven ^a  

^a Dept of Urology Mercy Medical Cter ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IODINE 125; PALLADIUM; PROSTATE SPECIFIC ANTIGEN;

ADULT; ARTICLE; BRACHYTHERAPY; CANCER SURVIVAL; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

EID: 0034061841     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2000.18.6.1187     Document Type: Article

References (29)

1. Holm HH, Torp-Pedersen S, Rasmussen F, et al: Ultrasound guided implantation of radioactive seeds. Prog Clin Biol Res 243B:45-48, 1987
2. Ragde H, Blasko JC, Grimm PD, et al: Interstitial iodine-125 radiation without adjuvant therapy in the treatment of clinically localized prostate carcinoma. Cancer 80:442-453, 1997
3. Beyer DC, Priestley JBJ: Biochemical disease-free survival following 1251 prostate implantation. Int J Radiat Oncol Biol Phys 37:559-563, 1997
4. Grado GL, Larson TR, Balch CS, et al: Actuarial disease-free survival after prostate cancer brachytherapy using interactive techniques with biplane ultrasound and fluoroscopic guidance. Int J Radiat Oncol Biol Phys 42:289-298, 1998
5. Bice WSJ, Prestidge BR, Grimm PD, et al: Centralized multiinstitutional postimplant analysis for interstitial prostate brachytherapy. Int J Radiat Oncol Biol Phys 41:921-927, 1998
6. Blasko JC, Ragde H, Grimm PD: Transperineal ultrasound-guided implantation of the prostate: Morbidity and complications. Scand J Urol Nephrol Suppl 137:113-118, 1991
7. Lee HH, Warde P, Jewett MA: Neoadjuvant hormonal therapy in carcinoma of the prostate. BJU Int 83:438-448, 1999
8. Bolla M, Gonzalez D, Warde P, et al: Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 337:295-300, 1997
9. Pilepich MV, Caplan R, Byhardt RW, et al: Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: Report of Radiation Therapy Oncology Group Protocol 85-31. J Clin Oncol 15:1013-1021, 1997
10. Fleming ID, Cooper JS, Henson DE, et al: AJCC Cancer Staging Manual (ed 5). Philadelphia, PA, Lippincitt-Raven, 1997
11. Bice WSJ, Prestidge BR, Prete JJ, et al: Clinical impact of implementing the recommendations of AAPM Task Group 43 on permanent prostate brachytherapy using 1251. Int J Radiat Oncol Biol Phys 40:1237-1241, 1998
12. Cha CM, Potters L, Ashley R, et al: Isotope selection for patients undergoing prostate brachytherapy. Int J Radiat Oncol Biol Phys 45:391-395, 1999
13. American Society for Therapeutic Radiology and Oncology Consensus Panel: Consensus statement: Guidelines for PSA following radiation therapy. Int J Radiat Oncol Biol Phys 37:1035-1041, 1997
14. Cox DR, Abadir R: Regression models and life tables. J R Stat Soc 34:187-220, 1972
15. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
16. Zelefsky MJ, Harrison A: Neoadjuvant androgen ablation prior to radiotherapy for prostate cancer: Reducing the potential morbidity of therapy. Urology 49:38-45, 1997
17. Bellon J, Wallner K, Ellis W, et al: Use of pelvic CT scanning to evaluate pubic arch interference of transperineal prostate brachytherapy. Int J Radiat Oncol Biol Phys 43:579-581, 1999
18. Gelblum D, Potters L, Ashley R, et al: Urinary morbidity following ultrasound-guided transperineal prostate seed implantation. Int J Radiat Oncol Biol Phys 45:59-67, 1999
19. Caubet JF, Tosteson TD, Dong EW, et al: Maximum androgen blockade in advanced prostate cancer: A meta-analysis of published randomized controlled trials using nonsteroidal antiandrogens. Urology 49:71-78, 1997
20. Eulau SM, Tate DJ, Stamey TA, et al: Effect of combined transient androgen deprivation and irradiation following radical prostatectomy for prostatic cancer. Int Radiat Oncol Biol Phys 41:735-740, 1998
21. Vicini FA, Kini VR, Spencer W, et al: The role of androgen deprivation in the definitive management of clinically localized prostate cancer treated with radiation therapy. Int J Radiat Oncol Biol Phys 43:707-713, 1999
22. D'Amico AV, Whittington R, Malkowicz SB, et al: Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280:969-974, 1998
23. Hanks GE, Hanlon AL, Schultheiss TE, et al: Dose escalation with 3D conformal treatment: Five year outcomes, treatment optimization, and future directions. Int J Radiat Oncol Biol Phys 41:501-510, 1998
24. Zelefsky MJ, Leibel SA, Gaudin PB, et al: Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer. Int J Radiat Oncol Biol Phys 41:491-500, 1998
25. Zelefsky MJ, Leibel SA, Kutcher GJ, et al: Three-dimensional conformal radiotherapy and dose escalation: Where do we stand? Semin Radiat Oncol 8:107-114, 1998
26. Zietman AL, Prince EA, Nakfoor BM, et al: Androgen deprivation and radiation therapy: Sequencing studies using the Shionogi in vivo tumor system. Int J Radiat Oncol Biol Phys 38:1067-1070, 1997
27. Mohan D, Kupelian P, Levin H, et al: Androgen deprivation in combination with surgery or radiotherapy for localized prostate cancer: When is it useful? J Clin Oncol 18:315A, 1999 (abstr 1210)
28. Smith JAJ: Management of hot flushes due to endocrine therapy for prostate carcinoma. Oncology 10:1319-1322, 1996
29. Oefelein MG: Time to normalization of serum testosterone after 3-month luteinizing hormone-releasing hormone agonist administered in the neoadjuvant setting: Implications for dosing schedule and neoadjuvant study consideration. J Urol 160:1685-1688, 1998